MDxHealth (MDXH) Competitors

MDxHealth (NASDAQ:MDXH) and Talis Biomedical (NASDAQ:TLIS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings, risk and community ranking.

Is MDXH or TLIS more profitable?

MDxHealth has a net margin of -49.52% compared to Talis Biomedical's net margin of -5,784.73%. Talis Biomedical's return on equity of -79.74% beat MDxHealth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MDxHealth	-49.52%	-1,077.84%	-28.82%
Talis Biomedical	-5,784.73%	-79.74%	-57.16%

Do analysts recommend MDXH or TLIS?

MDxHealth currently has a consensus price target of $7.00, indicating a potential upside of 332.10%. Given MDxHealth's stronger consensus rating and higher possible upside, analysts clearly believe MDxHealth is more favorable than Talis Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDxHealth	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Talis Biomedical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Does the media refer more to MDXH or TLIS?

In the previous week, MDxHealth had 4 more articles in the media than Talis Biomedical. MarketBeat recorded 4 mentions for MDxHealth and 0 mentions for Talis Biomedical. MDxHealth's average media sentiment score of 0.60 beat Talis Biomedical's score of 0.00 indicating that MDxHealth is being referred to more favorably in the media.

Company	Overall Sentiment
MDxHealth	Positive
Talis Biomedical	Neutral

Which has more volatility & risk, MDXH or TLIS?

MDxHealth has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500. Comparatively, Talis Biomedical has a beta of 1.56, indicating that its stock price is 56% more volatile than the S&P 500.

Do insiders & institutionals have more ownership in MDXH or TLIS?

43.8% of Talis Biomedical shares are held by institutional investors. 1.7% of MDxHealth shares are held by insiders. Comparatively, 46.0% of Talis Biomedical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Does the MarketBeat Community believe in MDXH or TLIS?

MDxHealth received 6 more outperform votes than Talis Biomedical when rated by MarketBeat users. Likewise, 55.56% of users gave MDxHealth an outperform vote while only 37.50% of users gave Talis Biomedical an outperform vote.

Company	Underperform	Outperform
MDxHealth	Outperform Votes 15 55.56%	Underperform Votes 12 44.44%
Talis Biomedical	Outperform Votes 9 37.50%	Underperform Votes 15 62.50%

Which has preferable earnings & valuation, MDXH or TLIS?

MDxHealth has higher revenue and earnings than Talis Biomedical. MDxHealth is trading at a lower price-to-earnings ratio than Talis Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDxHealth	$84.71M	0.03	-$43.10M	-$1.52	-1.07
Talis Biomedical	$300K	10.42	-$62.01M	-$28.02	-0.06

Summary

MDxHealth beats Talis Biomedical on 12 of the 18 factors compared between the two stocks.